Lexapro

(Escitalopram)

ApprovedSmall molecule

Escitalopram is used to treat depression and anxiety disorders by helping to balance chemicals in the brain that affect mood and emotions.[2] Lexapro is currently approved and in use across 64 indications[4].[1]

Lexapro is one of 1240 small molecule programs targeting Glioma. It is currently in Approved.

Indications

324

Total Trials

Active Trials

1,239

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Specific PhobiaActive, not recruiting

DyspepsiaActive, not recruiting

Bipolar I DisorderApproved

Depressive DisorderApproved

Psychiatric DisorderActive, not recruiting

SuicideActive, not recruiting

StrokeApproved

Acute Coronary SyndromeActive, not recruiting

Temporal Lobe EpilepsyActive, not recruiting

GliomaPhase 2

Active, not recruiting

Specific PhobiaPhase 2/Phase 3

Active, not recruiting

DyspepsiaPhase 2/Phase 3

Active, not recruiting

Bipolar I DisorderApproved

Approved

Depressive DisorderApproved

Approved

Psychiatric DisorderApproved

Active, not recruiting

SuicidePhase 2/Phase 3

Active, not recruiting

StrokeApproved

Approved

Acute Coronary SyndromeApproved

Active, not recruiting

Temporal Lobe EpilepsyApproved

Active, not recruiting

Showing 10 of 62 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

1 2

Gemzar

GGynecologic Oncology Group

MS Contin

1 4

Medrol

Pfizer

Preclinical

1 5

Byetta

AstraZeneca

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Chemotherapy Agents

Takeda

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

LDE225

Novartis

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Anxiety

NCT04623099

Phase 2Not yet recruiting

Major Depressive Disorder

NCT06705478

Phase 2Recruiting

Efficacy and Safety

NCT06828887

Q3 2027

Recruiting

Infants

NCT03511118

Q4 2027

Post-ApprovalRecruiting

Treatment

NCT07478796

Q2 2028

Phase 3Recruiting

First-Line Treatment

NCT05973786

Clinical

Trials by Indication[1]

Major Depressive Disorder35 trials

Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

Unknown status·—·Phase 4·NCT03122158·60 enrolled

Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·N/A·NCT03899194·350 enrolled

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

Completed·FForest Laboratories·Phase 3·NCT00107120·312 enrolled

Show 32 more trials

A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 2·NCT01034995·580 enrolled

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Completed· Otsuka logo

Otsuka·Phase 3·NCT01360866·2,944 enrolled

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·Phase 4·NCT01764867·1,080 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Terminated· Otsuka logo

Otsuka·Phase 3·NCT01111565·137 enrolled

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Completed·FForest Laboratories·Phase 3·NCT00109044·540 enrolled

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00432614·510 enrolled

Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT01997580·600 enrolled

Escitalopram in Adult Patients With Major Depressive Disorder

Completed·FForest Laboratories·Phase 3·NCT00668525·877 enrolled

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Unknown status·PPharmacology Research Institute·Phase 3·NCT00239954

Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder

Completed·SSamsung Medical Center·Phase 4·NCT01309776·164 enrolled

A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment

Unknown status·SShanghai Mental Health Center·Phase 4·NCT05145270·180 enrolled

Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder

Completed·KKRL Hospital, Islamabad·Phase 3·NCT05950061·744 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

Completed· GSK logo

GSK·Phase 3·NCT02191397·534 enrolled

An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01814098·318 enrolled

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00415142·393 enrolled

Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

Terminated·MMinistry of Health & Welfare, Korea·Phase 4·NCT00926835·692 enrolled

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00351910·494 enrolled

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

Completed· Otsuka logo

Otsuka·Phase 2·NCT05536414·337 enrolled

Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT01148472·294 enrolled

Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

Unknown status·PPeking University·N/A·NCT05389046·252 enrolled

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00135421·271 enrolled

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

Completed·LLehigh Center for Clinical Research·Phase 4·NCT00813735·60 enrolled

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Terminated· Otsuka logo

Otsuka·Phase 3·NCT01111539·211 enrolled

Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)

Unknown status·BBaker Heart and Diabetes Institute·Phase 4·NCT01483053·40 enrolled

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Completed· Sanofi logo

Sanofi·Phase 3·NCT00531622·643 enrolled

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Completed·SSadat City University·N/A·NCT04069819·80 enrolled

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Completed·MMassachusetts General Hospital·Phase 4·NCT00464711·40 enrolled

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06705478·186 enrolled

Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

Unknown status·SSheba Medical Center·Phase 4·NCT00442481·25 enrolled

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Completed· Takeda logo

Takeda·Phase 3·NCT01364649·447 enrolled

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

Completed·MMassachusetts General Hospital·Phase 4·NCT00183677·97 enrolled

Treatment Outcome in Major Depressive Disorder

Completed·RRigshospitalet, Denmark·Phase 1·NCT02869035·100 enrolled

Depression22 trials

Treatment of Depression in the Elderly

Terminated·—·Phase 4·NCT00130455·189 enrolled

Imaging Predictors of Treatment Response in Depression

Completed·EEmory University·N/A·NCT00367341·82 enrolled

RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD

Completed·PPeking University Sixth Hospital·N/A·NCT06758167·150 enrolled

Show 19 more trials

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

Unknown status·UUniversity Hospital Freiburg·Phase 3·NCT00837564·60 enrolled

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

Terminated·MMassachusetts General Hospital·Phase 4·NCT00955474·32 enrolled

Escitalopram (Lexapro) for Depression MS or ALS

Completed·UUniversity of South Carolina·Phase 3·NCT00965497·13 enrolled

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177294·319 enrolled

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00073411·675 enrolled

Treatment Response of Geriatric Depression

Completed·WWeill Medical College of Cornell University·N/A·NCT00754936·106 enrolled

Treatment of Depression in Adults

Completed·UUniversity of Pittsburgh·Phase 4·NCT00073697·290 enrolled

Dichotic Listening as a Predictor of Medication Response in Depression

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00404755·17 enrolled

Mechanisms of Antidepressant Non-Response in Late-Life Depression

Completed·NNew York State Psychiatric Institute·N/A·NCT01931202·138 enrolled

Canadian Biomarker Integration Network for Depression Study

Completed·UUniversity Health Network, Toronto·Phase 3·NCT01655706·211 enrolled

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

Completed·MMassachusetts General Hospital·Phase 4·NCT00452543·23 enrolled

The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

Completed·—·N/A·NCT02480400·52 enrolled

Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression

Completed·WWeill Medical College of Cornell University··NCT00926653·76 enrolled

International Study to Predict Optimised Treatment - in Depression

Unknown status·BBRC Operations Pty. Ltd.·Phase 4·NCT00693849·2,688 enrolled

The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression

Unknown status·SShanghai Mental Health Center·N/A·NCT04156425·180 enrolled

Escitalopram and Depression in Elderly Alzheimer's Patients

Terminated·UUniversity of British Columbia·Phase 3·NCT00488670·50 enrolled

The Quietude Study: Quetiapine Use for Agitated Depression

Terminated·PPhysicians Research And Education Network·Phase 3·NCT01363310·250 enrolled

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Recruiting·UUniversity of Cincinnati·Phase 4·NCT04245748·84 enrolled

Personalized Escitalopram Dosing in Patients With Depression

Unknown status·UUniversity of Belgrade··NCT05210140·148 enrolled

Treatment7 trials

Escitalopram Treatment of Night Eating Syndrome

Completed·—·N/A·NCT00636649·40 enrolled

Efficacy of Escitalopram in the Treatment of Internet Addiction

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT00565422·31 enrolled

Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment

Completed·UUniversity of Tartu·Phase 4·NCT03927950·135 enrolled

Show 4 more trials

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

Completed·NNew York State Psychiatric Institute·N/A·NCT00456014·37 enrolled

TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children

Recruiting·PPoznan University of Medical Sciences·Phase 4·NCT07478796·180 enrolled

Advancing Personalized Antidepressant Treatment Using PET/MRI

Completed·SStony Brook University·Phase 4·NCT02623205·85 enrolled

Investigation of a Combination Treatment of Escitalopram and rTMS

Completed·—·N/A·NCT00232700·42 enrolled

Major Depression6 trials

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)

Recruiting·NNova Scotia Health Authority·Phase 4·NCT05017311·400 enrolled

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

Completed·—·N/A·NCT00101452·199 enrolled

Lexapro and Pramipexole and to Treat Major Depression

Completed·NNational Institute of Mental Health (NIMH)·Phase 2·NCT00086307·39 enrolled

Show 3 more trials

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Completed·—·Phase 3·NCT00610506·15 enrolled

A Study for Participants With Major Depression

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00420004·469 enrolled

Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00917059·172 enrolled

Generalized Anxiety Disorder5 trials

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

Completed·VVeterans Medical Research Foundation·N/A·NCT00601965·73 enrolled

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00219349·25 enrolled

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00481325·260 enrolled

Show 2 more trials

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

Completed·—·Phase 3·NCT00887679·30 enrolled

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Completed· AbbVie logo

AbbVie·Phase 4·NCT03924323·273 enrolled

91 more indications

Treatment Resistant Depression5 trials

Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.

Completed·ZZhejiang University·Phase 1·NCT03887624·16 enrolled

A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression

Unknown status·SSheba Medical Center·N/A·NCT00220480·60 enrolled

Interpersonal Psychotherapy for Treatment Resistant Depression

Unknown status·HHospital de Clinicas de Porto Alegre·N/A·NCT01896349·74 enrolled

Show 2 more trials

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03852160

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03434041·252 enrolled

Obsessive-Compulsive Disorder4 trials

Treatment Youth With Obsessive-Compulsive Disorder

Unknown status·UUniversity of Ottawa·Phase 4·NCT00708240·40 enrolled

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Completed·—·Phase 2·NCT00215137·14 enrolled

Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)

Completed·—·Phase 3·NCT00305500·100 enrolled

Show 1 more trial

Predicting Medication Response in Obsessive Compulsive Disorder

Completed·SSunnybrook Health Sciences Centre·N/A·NCT01404871·26 enrolled

ESS4 trials

Does Dual Therapy Hasten Antidepressant Response?

Completed·NNew York State Psychiatric Institute·Phase 4·NCT00519428·245 enrolled

Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response

Completed·IIndiana University School of Medicine·Phase 4·NCT00456430·80 enrolled

Connectivity Affecting the Antidepressant REsponse Study

Completed·VVanderbilt University Medical Center·Phase 4·NCT02332291·95 enrolled

Show 1 more trial

Study of Neural Responses Induced by Antidepressant Effects

Completed·MMarta Peciña, MD PhD·Phase 2/3·NCT02674529·60 enrolled

Schizophrenia3 trials

Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

Completed·EEmory University·Phase 4·NCT00231335·30 enrolled

The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia

Completed·—·Phase 3·NCT00148447·40 enrolled

Escitalopram in Schizophrenia in OCD- Open Label Study

Completed·—·Phase 4·NCT00456937·15 enrolled

Post-Traumatic Stress Disorder3 trials

Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder

Completed·VVA Nebraska Western Iowa Health Care System·Phase 4·NCT01271244·26 enrolled

Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram

Completed·HHadassah Medical Organization·N/A·NCT00736021·38 enrolled

Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder

Completed·NNorthern California Institute of Research and Education·N/A·NCT01024140·16 enrolled

Alzheimer's Disease3 trials

Escitalopram for the Treatment of Depression in Alzheimer's Disease

Completed·KKonkuk University Medical Center·Phase 4·NCT01841125·84 enrolled

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

Completed·—·Phase 4·NCT01119638·40 enrolled

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

Completed·SSeoul National University Hospital·N/A·NCT00702780·74 enrolled

Anxiety3 trials

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

Recruiting·UUniversity of Cincinnati·Phase 4·NCT04245436·60 enrolled

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

Completed·UUniversity of Cincinnati·N/A·NCT02818751·84 enrolled

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

Recruiting·UUniversity of Cincinnati·Phase 4·NCT04623099·132 enrolled

Insomnia2 trials

Brain Mechanisms and Targeting Insomnia in Major Depression

Unknown status·UUniversity of California, Los Angeles·Phase 4·NCT00628914·60 enrolled

Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome

Completed·SStanford University·Phase 2·NCT00149825·30 enrolled

Pilot Study2 trials

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Terminated·UUniversity of Pennsylvania·Phase 4·NCT00523705·11 enrolled

Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study

Completed·UUniversity of Pittsburgh·Phase 4·NCT00222820·35 enrolled

Dyspepsia2 trials

Functional Dyspepsia Treatment Trial

Completed·MMayo Clinic·Phase 2/3·NCT00248651·292 enrolled

SSRI Study for Functional Dyspepsia (SS)

Completed·—·Phase 3·NCT02153567·71 enrolled

Head and Neck Cancer2 trials

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00935675·100 enrolled

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

Completed·UUniversity of Nebraska·Phase 4·NCT00536172·160 enrolled

Effectiveness2 trials

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

Completed·—·Phase 4·NCT03131050·66 enrolled

Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder

Completed·MMassachusetts General Hospital·Phase 3·NCT00149799·100 enrolled

Bipolar Depression2 trials

Treatment Resistant Bipolar Depression

Terminated·QQueen's University·Phase 1·NCT00272025·1 enrolled

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Completed·LLoyola University·Phase 4·NCT01479829·100 enrolled

Antidepressants2 trials

Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD

Completed·SSykehuset Innlandet HF·Phase 4·NCT00433121·24 enrolled

A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression

Unknown status·YYuqi Cheng·Phase 1·NCT03623711·200 enrolled

Depressive Symptoms2 trials

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

Completed·EEmory University·Phase 4·NCT00352885·20 enrolled

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT00642694·29 enrolled

Prevention2 trials

PTSD Prevention Using Escitalopram

Completed·SSheba Medical Center·N/A·NCT00300313·450 enrolled

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Terminated·HHillerod Hospital, Denmark·Phase 4·NCT00660062·47 enrolled

Magnetic Resonance Imaging2 trials

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01045083·25 enrolled

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

Completed·IIndiana University School of Medicine·Phase 4·NCT00707863·17 enrolled

Stroke2 trials

The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients

Unknown status·—·Phase 4·NCT01278498·444 enrolled

Escitalopram Treatment In Acute Stroke

Withdrawn·UUniversity of Aarhus·Phase 4·NCT01561092

Adult1 trial

Antidepressant Response in Older Adults With Comorbid PTSD and MDD

Terminated·NNew York State Psychiatric Institute·Phase 4·NCT04697693·1 enrolled

Platelet Function1 trial

Depression, Epinephrine, and Platelet Function

Completed·EEmory University·Phase 4·NCT00166114·40 enrolled

First-line Treatment1 trial

The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973786·418 enrolled

AIN1 trial

Brain Effects of Escitalopram and Citalopram Using fMRI

Completed·—·Phase 4·NCT00825825·27 enrolled

Elective1 trial

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 4·NCT03779789·362 enrolled

Asthma1 trial

Escitalopram in Asthma Patients With Frequent Exacerbation

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06216535·105 enrolled

Fibromyalgia1 trial

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

Completed·SShaheed Zulfiqar Ali Bhutto Medical University·Phase 2/3·NCT03487211·200 enrolled

Aging1 trial

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Withdrawn·AAlto Neuroscience·Phase 4·NCT04388202

Pancreatic Cancer1 trial

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Terminated·—·Phase 2·NCT05289830·4 enrolled

Acute1 trial

Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

Completed·—·Phase 4·NCT00419471·300 enrolled

Postmenopausal Women1 trial

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00406640·595 enrolled

Addiction1 trial

Clinical Neurobiology of Serotonin and Addiction

Completed·VVirginia Commonwealth University·Phase 2/3·NCT00732901·160 enrolled

Severe Depression1 trial

Mineralocorticoid Receptor in the Treatment of Severe Depression

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00295347·65 enrolled

Temporal Lobe Epilepsy1 trial

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

Completed·—·Phase 4·NCT00595699·8 enrolled

Dementia1 trial

Dementia Antipsychotics And Antidepressants Discontinuation Study

Completed·SSykehuset Innlandet HF·Phase 4·NCT00594269·149 enrolled

Specific Phobia1 trial

Study of Escitalopram in the Treatment of Specific Phobia

Completed·—·Phase 2/3·NCT00121069·12 enrolled

In Vitro Fertilization (IVF)1 trial

The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT00989053·120 enrolled

Tics1 trial

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01418274·20 enrolled

Facial Pain1 trial

Sinusitis and Facial Pain Disorders Anti-Depression Trial

Terminated·UUniversity of Washington·Phase 4·NCT00754793·3 enrolled

Bipolar Disorder1 trial

Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

Terminated·UUniversity of British Columbia·Phase 3·NCT00958633·237 enrolled

Vascular Dementia1 trial

Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia

Unknown status·SSheba Medical Center·Phase 4·NCT00229333·40 enrolled

End-Stage Renal Disease1 trial

The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT02407821·25 enrolled

Premature Ejaculation1 trial

Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation

Unknown status·—·Phase 1·NCT00656552·100 enrolled

Agitation1 trial

Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting·JJHSPH Center for Clinical Trials·Phase 3·NCT03108846·187 enrolled

Executive Dysfunction1 trial

Aging Brain Changes, Executive Dysfunction and Depression

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00918684·116 enrolled

Suicide1 trial

Treatment of Adolescent Suicide Attempters (TASA)

Completed·NNew York State Psychiatric Institute·Phase 2/3·NCT00080158·120 enrolled

Maintenance Treatment1 trial

Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment

Terminated·NNordfjord Psychiatric Centre·Phase 4·NCT00464191·150 enrolled

Cancer1 trial

Mirtazapine in Cancer-related Poly-symptomatology

Terminated·HHospices Civils de Lyon·Phase 3·NCT04763135·1 enrolled

Prophylaxis1 trial

Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment

Completed·FFoundation for Liver Research·Phase 2/3·NCT00133276·80 enrolled

Irritable Bowel Syndrome1 trial

Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder

Completed·MMaastricht University Medical Center·Phase 4·NCT01551225·32 enrolled

Total Knee Arthroplasty1 trial

Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)

Completed·HHvidovre University Hospital·Phase 4·NCT01430520·120 enrolled

Withdrawal Syndrome1 trial

Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT00598052·40 enrolled

Hepatitis C1 trial

Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Completed·—·Phase 3·NCT00136318·208 enrolled

Conditioning1 trial

Influence of Escitalopram on Fear Conditioning

Completed·MMassachusetts General Hospital·Phase 4·NCT01398514·65 enrolled

Cytokines1 trial

The Effects of Escitalopram on Cytokines

Unknown status·—·N/A·NCT01587326·25 enrolled

Buprenorphine1 trial

SSRI and Buprenorphine

Completed·—·Phase 3·NCT00475878·147 enrolled

Shock1 trial

The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry

Completed·UUCLH/UCL Joint Research Office·N/A·NCT07074652·145 enrolled

Function1 trial

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

Completed·UUniversity of Cincinnati·N/A·NCT02553161·214 enrolled

Lactobacillus Plantarum1 trial

Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment

Completed·MMedical University of Bialystok·Phase 2·NCT02469545·60 enrolled

Remission1 trial

Lexapro®'s Efficacy After Dose Escalation in Remission Study

Completed·SSeoul National University Hospital·Phase 4·NCT01594866·60 enrolled

Biomarkers1 trial

Biomarkers of Antidepressant Response and Suicidal Events in Depressed Youth

Completed·SSeoul National University·N/A·NCT03547219·152 enrolled

Single Dose1 trial

A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram

Completed·KKarolinska Institutet·Phase 1·NCT01638689·10 enrolled

Infants1 trial

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting·—··NCT03511118·1,600 enrolled

Psychiatric Disorder1 trial

Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders

Completed·MMedical University of Vienna·Phase 4·NCT01477203·289 enrolled

Clinical Trial1 trial

A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers

Completed·SSeoul National University Hospital·Phase 1·NCT02122939·12 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT04446039·370,212 enrolled

Adolescent1 trial

Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT05945342·100 enrolled

Mechanical Ventilation1 trial

Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit

Completed·UUniversity of Minnesota·Phase 4·NCT00872027·15 enrolled

Borderline personality disorder1 trial

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Terminated·UUniversity of Chicago·Phase 2·NCT01103180·70 enrolled

Menopausal Symptoms1 trial

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Completed·FFred Hutchinson Cancer Center·N/A·NCT00894543·205 enrolled

Acute Coronary Syndrome1 trial

DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome

Unknown status·—·Phase 4·NCT00140257·240 enrolled

Electroencephalography1 trial

Electroencephalography (EEG) Signal Processing

Unknown status·SSt. Joseph's Healthcare Hamilton··NCT01369290·150 enrolled

Aripiprazole1 trial

Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole

Recruiting·—·N/A·NCT06937476·108 enrolled

Genetic Polymorphism1 trial

Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression

Completed·CCentre for Addiction and Mental Health·N/A·NCT00517764·299 enrolled

Myocardial Ischemia1 trial

Responses of Myocardial Ischemia to Escitalopram Treatment

Completed·—·Phase 4·NCT00574847·127 enrolled

Postpartum Depression1 trial

Escitalopram (Lexapro) for the Treatment of Postpartum Depression

Completed·MMassachusetts General Hospital·Phase 4·NCT00833469·7 enrolled

Completed· Lundbeck logo

Lundbeck·Phase 1·NCT01395433·32 enrolled

Social Anxiety Disorder1 trial

Escitalopram in Patients With Social Anxiety Disorder

Completed· Lundbeck logo

Lundbeck·Phase 4·NCT00902226·30 enrolled

Age1 trial

Developing New Clinical Management Strategies

Completed·NNew York State Psychiatric Institute·Phase 4·NCT02082392·3 enrolled

Cocaine Dependence1 trial

Modafinil - Escitalopram Study for Cocaine Dependence

Completed·—·Phase 1·NCT01601730·68 enrolled

Low Birth Weight1 trial

Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight

Completed·UUniversity of Aarhus·N/A·NCT00971815·60 enrolled

Efficacy and Safety1 trial

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD

Recruiting·VVigonvita Life Sciences·Phase 2·NCT06828887·400 enrolled

Brain Aging1 trial

Brain Aging and Treatment Response in Geriatric Depression

Completed·UUniversity of California, Los Angeles·Phase 4·NCT01902004·115 enrolled

Pulmonary Hypertension1 trial

Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00190333·30 enrolled

Brain Injury1 trial

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

Completed·JJohns Hopkins University·Phase 2·NCT01368432·16 enrolled

Epilepsy1 trial

Anxiety and Depression in Epilepsy: A Pilot Treatment Study

Withdrawn·WWake Forest University Health Sciences·Phase 4·NCT03522987

Rheumatoid Arthritis1 trial

Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis

Completed·TTanta University·Phase 3·NCT05480878·90 enrolled

PCOS1 trial

The Effect of Escitalopram in PCOS

Completed·OOdense University Hospital·Phase 4·NCT05840692·40 enrolled

Electroacupuncture1 trial

Effect of Electroacupuncture on Treating the First-episode Depression

Recruiting·SShanghai Municipal Hospital of Traditional Chinese Medicine·N/A·NCT05818735·204 enrolled

Burning Mouth Syndrome1 trial

Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome

Unknown status·FFederico II University·Phase 3·NCT06025474·203 enrolled

Unspecified6 trials

Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning

Unknown status·SSamsung Medical Center·N/A·NCT00935246·202 enrolled

EScitalopram PIndolol ONset of Action

Terminated·MMarkus KOSEL·Phase 2/3·NCT01219686·18 enrolled

Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

Completed·MMedical University of Vienna·Phase 4·NCT01251471·26 enrolled

Show 3 more trials

Specific Effects of Escitalopram on Neuroendocrine Response

Completed·QQueen's University··NCT00150527·8 enrolled

AZD7268 Safety and Tolerability Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01020799·247 enrolled

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 14, 2002

LEXAPRO

NDA NDA021323

Nov 27, 2002

LEXAPRO

NDA NDA021365

Aug 29, 2025

ESCITALOPRAM

NDA NDA219130

Sources

References

[1]
ClinicalTrials.gov — 324 trial records for Escitalopram. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Lexapro drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Escitalopram compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Escitalopram. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219130). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serotonin Transporter Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie